Preferred Label : Inotersen;

UNII : 0IEO0F56LV;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-marr/inotersen
2024
false
false
false
France
French
risk management
Inotersen
inotersen
Drug-Related side effects and adverse reactions
patients guideline
drug information
eye diseases
glomerulonephritis
thrombocytopenia
oligonucleotides
oligodeoxyribonucleotides, antisense

---
https://www.has-sante.fr/portail/jcms/c_2965636/fr/tegsedi
2019
false
true
false
false
France
French
treatment outcome
orphan drug production
amyloidosis, hereditary, Transthyretin-Related
injections, subcutaneous
oligonucleotides, antisense
adult
aged
evaluation of the transparency committee
polyneuropathies
inotersen
amyloid neuropathies, familial
Inotersen
oligonucleotides

---
https://www.has-sante.fr/jcms/p_3106176/fr/tegsedi
2019
false
false
false
France
inotersen
Inotersen
evaluation of the transparency committee
Inotersen
oligonucleotides

---
https://www.ema.europa.eu/medicines/human/EPAR/Tegsedi
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
drug approval
europe
amyloidosis, hereditary, Transthyretin-Related
injections, subcutaneous
continuity of patient care
oligonucleotides, antisense
oligonucleotides, antisense
amyloid neuropathies
drug interactions
pregnancy
adult
aged
drug evaluation, preclinical
inotersen
polyneuropathies
amyloid neuropathies, familial
Inotersen
Inotersen
oligonucleotides
oligonucleotides

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.